Characteristic behavioral alterations in rats induced by rolipram and other selective adenosine cyclic 3?,5?-monophosphate phosphodiesterase inhibitors
- 1 August 1982
- journal article
- research article
- Published by Springer Nature in Psychopharmacology
- Vol. 77 (4) , 309-316
- https://doi.org/10.1007/bf00432761
Abstract
The significance of a characteristic symptomatology (hypothermia, hypoactivity, forepaw shaking, grooming, head twitches) as a potential in vivo correlate of enhanced availability of brain adenosine cyclic 3′,5′-monophosphate (cAMP) was examined in rats following systemic administration of various doses of dibutyryladenosine cAMP (dBcAMP) or of the phosphodiesterase (PDE) inhibitors rolipram, Ro 20-1724, ICI 63-197, isobutylmethylxanthine (IBMX), theophylline, cartazolate, and papaverine. The various PDE inhibitors could be assigned to three groups according to the pattern of behavioral alterations they induced. Rolipram, Ro 20-1724, and ICI 63-197 (group 1) caused hypothermia, hypoactivity, forepaw shaking, grooming, and head twitches. All behavioral effects were mimicked by dBcAMP but not dBcGMP. The order of potency and effective dosage range to induce the behavioral alterations were, in descending order, rolipram (0.09–1453 μmol/kg IP), ICI 63-197 (0.48–119 μmol/kg IP), Ro 20-1724 (5.6-1438 μmol/kg IP), corresponding with the recently reported efficacy of the drugs to elevate rat brain cAMP in vivo. Comparatively high doses of the alkylxanthine PDE inhibitors IBMX and theophylline (group 2) caused hypothermia, forepaw shaking, grooming, and head twitches concomitantly with a decline of the motor stimulatory effect, suggesting enhanced availability of brain cAMP. The order of potency and the effective dosage range to induce the behavioral alterations were, in descending order, IBMX (28.1–113 μmol/kg IP) and theophylline (139–555 μmol/kg IP). The third group, papaverine (295–1179 μmol/kg IP) and cartazolate (21.5–345 μmol/kg IP), caused only hypothermia and hypoactivity. The differences in the behavioral pattern of the two latter groups of compounds in comparison with dBcAMP and the selective cAMP PDE inhibitors are discussed with regard to their additional interference with adenosine actions besides their nonselective PDE inhibitory action.This publication has 31 references indexed in Scilit:
- Mechanism of quasi-morphine withdrawal behaviour induced by methylxanthinesEuropean Journal of Pharmacology, 1979
- Effect of some phosphodiesterase inhibitors on two different preparations of adenosine 3′,5′-monophosphate phosphodiesteraseCellular and Molecular Life Sciences, 1975
- Morphine abstinence and quasi-abstinence effects after phosphodiesterase inhibitors and naloxoneLife Sciences, 1975
- Adenosine-elicited accumulation of cyclic AMP in brain slices: Potentiation by agents which inhibit uptake of adenosineLife Sciences, 1974
- Preliminary data on the possible hypnogenic role of adenosine1Journal of Neurochemistry, 1973
- Accumulation of cyclic adenosine monophosphate in incubated slices of brain tissue. 2. Effects of depolarizing agents, membrane stabilizers, phosphodiesterase inhibitors, and adenosine analogsJournal of Medicinal Chemistry, 1972
- Cyclic Adenosine Monophosphate Phosphodiesterase in Brain: Effect on AnxietyScience, 1972
- The effect of caffeine and theophylline on the disposition of brain serotonin in the ratEuropean Journal of Pharmacology, 1971
- Effects of derivatives of adenosine 3′,5′-phosphate on liver slices and intact animalsBiochimica et Biophysica Acta (BBA) - General Subjects, 1967
- Injections of drugs into the lateral ventricle of the catThe Journal of Physiology, 1954